Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements

by TipRanks, Benzinga Contributor

April 27, 2024 7:35 AM | 6 seconds read | Make a Comment

Capricor Therapeutics (CAPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCa...

Market News and Data brought to you by Benzinga APIs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Buy Rating Affirmed for Capricor Therapeutics Amidst Positive FDA Discussions and Clinical Advancements